JPRN-jRCT2031230572尚未招募3 期
Phase III clinical evaluation of WBCRRD and SPB-KT in patients receiving continuous blood purification therapy (CBP)
Kinoshita Kaori0 个研究点目标入组 344 人开始时间: 2024年1月18日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 344
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
入选标准
- •Written informed consent from patients or legal representative if patients lack of ability to consent.
- •- Over 20 years of age at the time of acquiring consent.
- •- Indications: Fluid overload, Metabolic acidosis, Urine output, Electrolytes disturbance, Intoxication, Cytokine abnormal, Severe pancreatitis acute, Hepatitis fulminant or Postoperative hepatic failure.
排除标准
- •- Patients who find it difficult to receive treatment under the conditions specified in the study protocol.
- •- Patients who are pregnant at the time of consent for this study.
- •- Patients participating in other clinical studies at the time of consent for this study.
- •- Patients judged to be inadequate for this study by the investigators .
研究者
相似试验
招募中
3 期
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerEndometrial CancerNCT06340568BioNTech SE480
进行中（未招募）
3 期
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT06448312Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.406
招募中
3 期
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerMetastatic Breast CancerNCT06081959Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.376
招募中
3 期
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapyEssential HypertensionType 2 Diabetes MellitusNCT06220773Boryung Pharmaceutical Co., Ltd276
招募中
3 期
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerTriple Negative Breast CancerNCT06279364Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.524